The priorities of the Pilot Grant Program include:
- Identifying treatment-responsive biomarkers
- Assessing clinical measures that enhance clinical trial readiness
- Evaluating therapeutic interventions for one or more of the five distinct subtypes of MG
Pilot studies must be designed to access the resources of MGNet and focused on clinical research, including fulfilling the definition of clinical research and exclusion of animal studies.
Letters of intent are due December 17, 2021. Full proposals are due March 11, 2022.
The Myasthenia Gravis Rare Disease Network (MGNet) is part of the Rare Diseases Clinical Research Network (RDCRN), which is funded by the National Institutes of Health (NIH) and led by the National Center for Advancing Translational Sciences (NCATS) through its Office of Rare Diseases Research (ORDR). MGNet is funded under grant number U54NS115054 as a collaboration between NCATS and the National Institute of Neurological Disorders and Stroke (NINDS).